Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.36 |
| ▸ | HTR3B | O95264 | 2/20 | 0.36 |
| ▸ | HTR3A | P46098 | 2/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP4 | P49662 | 1/20 | 0.35 |
| ▸ | CASP5 | P51878 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17934702 | 0.79 | — | — | |
| SCHEMBL18052759 | 0.79 | ADRB1 (0.41) | ALDH1A1KDM4EADRB1HTR3EHTR3B | |
| SCHEMBL29980540 | 0.76 | ADRA2C (0.34) | ALDH1A1KDM4EHTR3EHTR3BHTR3A | |
| SCHEMBL30425332 | 0.76 | LMNA (0.36) | ALDH1A1KDM4EUSP2LMNA | |
| SCHEMBL20483904 | 0.72 | ADRB1 (0.47) | ALDH1A1KDM4EADRB1HTR3EHTR3B | |
| SCHEMBL19120784 | 0.72 | MAPT (0.46) | ALDH1A1ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL20780839 | 0.72 | — | — | |
| SCHEMBL12663101 | 0.72 | CHRNA7 (0.42) | ALDH1A1KDM4EUSP2SMN1; SMN2LMNA | |
| SCHEMBL31696522 | 0.71 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL1709261 | 0.71 | NPC1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113214287-B | HPK1 inhibitors and methods of use thereof | 大学健康网络 | 2023-10-20 | — | — | CN | disclosed |
| US-20170290825-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. | 2017-10-12 | — | — | US | disclosed |
| WO-2009123221-A1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | 全薬工業株式会社 (JP) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290825-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | PCK1, PDK3, PDK2 | ALDH1A1 1517/4885KDM4E 2079/4885ADRB1 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.